An investigational device could help interventional cardiologists avoid the limitations of drug-eluting stents, according to a new analysis published in JACC.
It was another strong quarter for Edwards Lifesciences as the company's TAVR platform continues to gain momentum. The FDA's approval of multiple Edwards valves for the treatment of asymptomatic severe AS represents a potential game-changer for the entire industry.
Neil G. Bluhm, a billionaire philanthropist with deep ties to Chicago, has donated an additional $50 million to a high-volume facility that already bears his name.
The BioCardia delivery catheter was designed to be used by interventional cardiologists, electrophysiologists or cardiac surgeons. It includes a tiny needle that directly engages with the patient’s cardiac tissue.
The American College of Radiology recently brought together thought leaders from 32 different organizations to come up with ways to standardize care when using this popular imaging system.
In other news, NYU Langone Health recently named a new radiation oncology chair, a Lumexa Imaging rad is joining the RSNA board, and SNMMI has appointed an editor for its flagship journal.
An investigational device could help interventional cardiologists avoid the limitations of drug-eluting stents, according to a new analysis published in JACC.
